Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive Not Recruiting
NCT04130516Phase 1, Phase 2Updated Jul 13, 2026
Sponsor: Linnaeus Therapeutics, Inc.
Solid Tumor, Adult
United States
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)Recruiting
NCT07199465Phase 1Updated Jul 13, 2026
Sponsor: Merck Sharp & Dohme LLC
Cytomegalovirus Prophylaxis
United States
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast CancerRecruiting
NCT06976944Phase 2Updated Jul 13, 2026
Sponsor: Yukinori Ozaki
Recurrent Triple-Negative Breast Cancer
Japan
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Recruiting
NCT06637423Phase 1, Phase 2Updated Jul 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-Muscle Invasive Bladder Cancer
United States, Canada, France, Netherlands, Spain +1 more
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform NeurofibromasActive Not Recruiting
NCT03962543Phase 2Updated Jul 10, 2026
Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Plexiform Neurofibroma · Neurofibromatosis Type 1 (NF1)
United States
METformin and FINGER Intervention to Prevent Cognitive Impairment and Disability in Older Adults at Risk for DementiaActive Not Recruiting
NCT05109169Phase 2Updated Jul 10, 2026
Sponsor: Imperial College London
Cognitive Decline · Cognitive Impairment · Dementia
Finland, Sweden, United Kingdom
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)Terminated
NCT06113328Phase 2Updated Jul 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Non-segmental Vitiligo
United States, Argentina, Australia, Belgium, Canada +13 more
A Study Evaluating ANV600 Single Agent or in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (EXPAND-1)Completed
NCT06470763Phase 1, Phase 2Updated Jul 10, 2026
Sponsor: Anaveon AG
Advanced Solid Tumor
United States, Belgium, France, Germany, Netherlands +2 more
Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland CarcinomaActive Not Recruiting
NCT03942653Phase 2Updated Jul 10, 2026
Sponsor: Manish Patel
Salivary Gland Carcinoma
United States
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-ThalassemiaRecruiting
NCT04143724Phase 2Updated Jul 10, 2026
Sponsor: Celgene
Beta-Thalassemia
United States, China, Germany, Greece, India +4 more
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)Recruiting
NCT06780098Phase 2Updated Jul 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Lung Neoplasm
United States, Chile, China, Germany, Greece +6 more
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Active Not Recruiting
NCT06428396Phase 2Updated Jul 10, 2026
Sponsor: Merck Sharp & Dohme LLC
Metastatic Breast Cancer
United States, Argentina, Canada, Chile, Colombia +4 more
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)Recruiting
NCT05482893Phase 1, Phase 2Updated Jul 9, 2026
Sponsor: Phanes Therapeutics
Gastric or Gastroesophageal Junction Adenocarcinoma · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer (BTC)
United States
Sotatercept in Pulmonary Arterial HypertensionRecruiting
NCT07140484Phase 4Updated Jul 9, 2026
Sponsor: University of Alberta
Pulmonary Artery Hypertension
Canada
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)Completed
NCT03834493Phase 3Updated Jul 9, 2026
Sponsor: Merck Sharp & Dohme LLC
Prostatic Neoplasms
United States, Argentina, Australia, Austria, Brazil +23 more
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular CarcinomaCompleted
NCT03519997Phase 2Updated Jul 8, 2026
Sponsor: David Hsieh
Hepatocellular Carcinoma
United States
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]Active Not Recruiting
NCT03747120Phase 2Updated Jul 8, 2026
Sponsor: University of Texas Southwestern Medical Center
HER2-positive Breast Cancer · Breast Cancer
United States
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)Recruiting
NCT04375800Phase 2Updated Jul 8, 2026
Sponsor: Merck Sharp & Dohme LLC
Human Immunodeficiency Virus (HIV) Infection
United States, Colombia, Mexico, Russia, South Africa +1 more
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric CancerRecruiting
NCT06123338Phase 2Updated Jul 7, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Esophageal Cancer · Gastric Adenocarcinoma · HER2 Gene Mutation
United States
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)Recruiting
NCT06780137Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer
United States, Argentina, Australia, Chile, China +7 more
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)Recruiting
NCT02332668Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma · Lymphoma · Solid Tumor · Classical Hodgkin Lymphoma
United States, Brazil, France, Germany, Israel +5 more
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)Completed
NCT03976323Phase 3Updated Jul 6, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Nonsquamous Non-small-cell Lung
United States, Argentina, Australia, Austria, Brazil +15 more
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid TumorsCompleted
NCT04609566Phase 2Updated Jul 6, 2026
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Melanoma · Non-small Cell Lung Cancer · Squamous Cell Carcinoma of the Head and Neck
United States
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast CancerRecruiting
NCT06110793Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Metastatic Breast Cancer
United States
An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and SwedenActive Not Recruiting
NCT06053749N/AUpdated Jul 6, 2026
Sponsor: Bayer
Multiple Sclerosis (MS)
Finland, Sweden

Previous page Next page